Go to the list of all blogs
M. Benett's Avatar
published in Blogs
May 21, 2026
Marvell Technology (MRVL) Stock Gains +23% Over 30 Days and +122% This Quarter

Marvell Technology (MRVL) Stock Gains +23% Over 30 Days and +122% This Quarter

Key Takeaways

  • MRVL stock rose approximately +23% over the past 30 days, driven by sustained momentum in artificial intelligence demand and positive analyst sentiment.
  • Over the past quarter, the stock advanced more than +122%, reflecting robust growth in data center revenue and upgraded fiscal guidance.
  • Strong fourth-quarter fiscal 2026 earnings results, including record revenue of $8.195 billion, served as a primary catalyst for the quarterly advance.
  • Analyst upgrades, including Bank of America raising its rating to Buy, contributed to improved market sentiment.
  • Broader semiconductor sector tailwinds from AI infrastructure spending supported the price movement amid favorable macroeconomic conditions.

A Closer Look at Marvell Technology (MRVL) and Its Market Position

Marvell Technology, Inc. designs and develops semiconductors and related solutions for data infrastructure, including networking, storage, and custom application-specific integrated circuits. The company’s core business model focuses on providing high-performance chips for cloud computing, artificial intelligence, and enterprise applications. Operating primarily in the semiconductor industry, Marvell competes with peers in the custom silicon and connectivity segments. Its strong exposure to AI-driven data center spending and optical connectivity solutions helps explain recent stock behavior, as these areas have seen accelerating demand. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

MRVL Stock Performance: +23% in the Last 30 Days vs. +122% Over the Quarter

Over the last 30 days, MRVL shares increased approximately +23%, moving from around $151 to $186.80 on a closing basis. The advance occurred in a relatively steady upward trend with some volatility around earnings-related periods, remaining range-bound early before accelerating on positive momentum.

Over the last quarter, the stock rose more than +122%, advancing from levels near $79–$80 to $186.80. This performance reflected a sustained upward trajectory supported by multiple positive catalysts, with limited pullbacks and consistent buying interest from institutional investors. From what I see, the longer-term move highlights how quickly sentiment can shift when data center trends align with company execution.

What Drove the +23% Gain in MRVL Stock Over the Last 30 Days

The 30-day gain stemmed primarily from continued investor enthusiasm following the March earnings release and subsequent guidance updates. Company-specific news around expanded custom AI silicon programs and optical interconnect solutions reinforced positive sentiment. Analyst upgrades, such as Bank of America moving to a Buy rating with a higher price target, added further support. Sector-wide demand for AI infrastructure provided macroeconomic tailwinds, while market sentiment shifted favorably as data center spending trends remained strong. These factors combined to drive steady buying pressure and limit downside volatility during the period.

What Drove the +122% Advance in MRVL Stock Over the Last Quarter

The broader three-month advance was propelled by larger narratives around Marvell’s positioning in the AI ecosystem. Fiscal 2026 results delivered record revenue of $8.195 billion, up 42% year over year, with particular strength in data center products. Upward revisions to fiscal 2027 and 2028 revenue outlooks highlighted expected growth exceeding 30% annually. Competitive positioning in custom chips and high-speed connectivity improved as hyperscale customers increased orders. Institutional buying accelerated amid favorable macroeconomic conditions, including steady interest rates and robust technology capital expenditures. These sustained forces delivered the strongest cumulative impact on the stock throughout the quarter.

How I Incorporate Tickeron AI Tools Into My Research Process

When analyzing names like MRVL, I often turn to Tickeron’s AI tools to scan for patterns and compare performance across the semiconductor group. One resource I find particularly useful is the Trending AI Robots page, which highlights a selection of top-performing automated strategies that trade equities including MRVL. While Tickeron offers many bots with varying timeframes and approaches, this curated view helps me quickly identify options that align with current market conditions without having to review every available strategy.

MRVL Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor the upcoming first-quarter fiscal 2027 earnings release for updates on revenue and margins. Key industry trends in artificial intelligence infrastructure spending and data center expansion remain important to track. Macroeconomic factors, including interest rate movements and overall technology capital expenditure levels, could influence sentiment. Strategic developments such as new custom chip wins or partnerships in optical connectivity also warrant attention. Potential risks include supply chain disruptions or shifts in customer spending patterns. I’m watching this closely because any miss on guidance could quickly reverse some of the recent momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MRVL

Aroon Indicator for MRVL shows an upward move is likely

MRVL's Aroon Indicator triggered a bullish signal on October 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 224 similar instances where the Aroon Indicator showed a similar pattern. In 198 of the 224 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on MRVL as a result. In 72 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for MRVL just turned positive on September 16, 2026. Looking at past instances where MRVL's MACD turned positive, the stock continued to rise in 40 of 51 cases over the following month. The odds of a continued upward trend are 78%.

MRVL moved above its 50-day moving average on September 04, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRVL advanced for three days, in 248 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRVL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

MRVL broke above its upper Bollinger Band on September 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRVL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.210) is normal, around the industry mean (7.902). P/E Ratio (83.411) is within average values for comparable stocks, (163.223). Projected Growth (PEG Ratio) (1.340) is also within normal values, averaging (3.705). Dividend Yield (0.001) settles around the average of (0.007) among similar stocks. P/S Ratio (21.552) is also within normal values, averaging (45.163).

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), Broadcom Inc. (NASDAQ:AVGO), Micron Technology (NASDAQ:MU), Advanced Micro Devices (NASDAQ:AMD), Intel Corp (NASDAQ:INTC), Texas Instruments (NASDAQ:TXN), Marvell Technology (NASDAQ:MRVL), QUALCOMM (NASDAQ:QCOM), Analog Devices (NASDAQ:ADI).

Industry description

The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.

Market Cap

The average market capitalization across the Semiconductors Industry is 216.18B. The market cap for tickers in the group ranges from 86.8K to 5.53T. NVDA holds the highest valuation in this group at 5.53T. The lowest valued company is STRB at 86.8K.

High and low price notable news

The average weekly price growth across all stocks in the Semiconductors Industry was 5%. For the same Industry, the average monthly price growth was 12%, and the average quarterly price growth was 51%. WOLF experienced the highest price growth at 22%, while MOBX experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Semiconductors Industry was 5%. For the same stocks of the Industry, the average monthly volume growth was -0% and the average quarterly volume growth was -57%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 51
Price Growth Rating: 41
SMR Rating: 72
Profit Risk Rating: 71
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
MRVL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in the business of providing semiconductors to high-performance application-specific standard products

Industry Semiconductors

Industry
Semiconductors
Address
1000 N. West Street
Phone
+1 302 295-4840
Employees
7480
Web
https://www.marvell.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.